Toni Stephenson Lymphoma Center Featured Clinical Trials

  • Phase 2 Front-Line PET/CT-2 Response-Adapted Brentuximab Vedotin and Nivolumab Incorporated and Radiation-Free Management of Early Stage Classical Hodgkin Lymphoma (NCT03712202
    Principal investigator email: Alex Herrera 
  • Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma (S1826) (NCT03907488
    Principal investigator email: Alex Herrera 
  • Phase 1/2 Study of Copanlisib and Venetoclax in Patients With Relapsed or Refractory Mantle Cell Lymphoma (NCT04939272
    Principal investigator email: Alexey Danilov 
  • Phase 1b Study to Evaluate CD19-Specific Chimeric Antigen Receptor (CAR)-T Cells Combined With Acalabrutinib for Patients With Relapsed or Refractory Mantle Cell Lymphoma (NCT04484012
    Principal investigator email: Elizabeth Budde 
  • Phase 1 Study Evaluating BAFFR-Targeting CAR T cells for Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NCT05370430
    Principal investigator email: Elizabeth Budde 
  • Phase 2 Study of Loncastuximab Tesirine Plus Mosunetuzumab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (expected to open early 2023) 
    Principal investigator email: Swetha Kambhampati 
  • Phase 1/2 Trial of Durvalumab (MEDI4736) When Given as a Single Agent or in Combination With Lenalidomide in Patients With Relapsed/ Refractory Peripheral T-cell Lymphoma, Including Cutaneous T-cell Lymphoma (NCT03011814
    Principal investigator email: Christiane Querfeld  
  • Phase 1B, Pilot Study to Assess the Pharmacodynamics, Pharmacokinetics, Safety, and Activity of STI-2949 anti-PD-1 Monoclonal Antibody Administered Lymphatically Using the Sofusa® DoseConnect Device in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma (STI-SOFUSA-1004) (NCT04118868
    Principal investigator email: Christiane Querfeld